Side effects of medications used to treat childhood interstitial lung disease
Interstitial lung disease in children (chILD) comprises a range of different rare diseases. There is limited evidence for the treatment of chILD and no randomised clinical trials of treatment have been undertaken. Most treatments are therefore prescribed off-label based on expert opinion. The off-label nature of prescription of drugs for chILD highlights the importance of a solid understanding of the side effects to facilitate risk-benefit assessment. The European Respiratory Society chILD guidelines recommend the use of systemic glucocorticosteroids, hydroxychloroquine and azithromycin.
Source: Paediatric Respiratory Reviews - Category: Respiratory Medicine Authors: Oded Breuer, Andr é Schultz Tags: Review Source Type: research
More News: Azithromycin | Children | Clinical Trials | Hydroxychloroquine | Interstitial Lung Disease | Pediatrics | Rare Diseases | Respiratory Medicine | Zithromax